Silco Pharmaceuticals Limited announcements
108 Dhaka Stock Exchange announcements for Silco Pharmaceuticals Limited (SILCOPHL) since 2020: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2020 (16).
- Trading of the shares of the Company will resume on 02.12.2020 after record date.
Trading of the shares of the Company will resume on 02.12.2020 after record date.
- Trading of the shares of the Company will remain suspended on record date i.e., 01.12.2020.
Trading of the shares of the Company will remain suspended on record date i.e., 01.12.2020.
- Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled
Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 29.11.2020 to 30.11.2020. Trading of the shares of the Company will remain suspended on record date i.e., 01.12.2020.
- (Q1 Un-audited): EPS was Tk. 0.33 for July-September 2020 as against Tk. 0.28 for July-September 2019; NOCFPS was Tk. 0.
(Q1 Un-audited): EPS was Tk. 0.33 for July-September 2020 as against Tk. 0.28 for July-September 2019; NOCFPS was Tk. 0.52 for July-September 2020 as against Tk. 0.41 for July-September 2019. NAV per share was Tk. 21.97 as on September 30, 2020 and Tk. 21.64 as on June 30, 2020.
- The auditor of the Silco Pharmaceuticals Limited has given the " Emphasis of Matter " paragraph in the Auditor 's Report
The auditor of the Silco Pharmaceuticals Limited has given the " Emphasis of Matter " paragraph in the Auditor 's Report for the year ended on 30 June 2020. Emphasis of Matter: We draw attention to note number 2.15 (b) and 14 to the Financial Statements regarding contribution to provision for Employees Profit Participation Fund (WPPF) in accordance with Bangladesh Labour Act, 2006(Amended-2013) and subsequent payment to beneficiaries of the fund. We emphasize (cont.)
- (Continuation news of SILCOPHL): on the certainty of the balance available Tk.6,254,023/- shown in the Statement of Fina
(Continuation news of SILCOPHL): on the certainty of the balance available Tk.6,254,023/- shown in the Statement of Financial Position as at 30th June, 2020. The adjusted current year Tk. 6,380,888/-(Note:14) should have been made through banking channel. The company made cash payments which are not recommended by the relevant regulation. It was hard for us to reconcile the actual payment made by the company from WPPF fund during the year under audit. (end)
The first part of this announcement is missing from the archive. - The Board of Directors has recommended 10% cash dividend (for all shareholders excluding Sponsors and Directors) for the
The Board of Directors has recommended 10% cash dividend (for all shareholders excluding Sponsors and Directors) for the year ended on June 30, 2020. Date of AGM: 24.12.2020, Time: 11:30 AM, Venue: Digital Platform. Record Date: 01.12.2020. The Company has reported EPS of Tk. 0.80, NAV per share of Tk. 21.64 and NOCFPS of Tk. 1.41 for the year ended on June 30, 2020 as against Tk. 2.02, Tk. 23.12 and Tk. 1.00 respectively for the same period of the previous year.
- There will be no price limit on the trading of the shares of the Company today (02.11.2020) following its corporate decl
There will be no price limit on the trading of the shares of the Company today (02.11.2020) following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.
- Dividend Declaration (Additional Information): The Company has further informed that the Sponsors and Directors hold 40,
Dividend Declaration (Additional Information): The Company has further informed that the Sponsors and Directors hold 40,608,370 shares out of total 103,807,000 shares of the Company and the cash dividend to be payable to the General shareholders is BDT. 6,31,98,630.00.
- As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 1, 2020 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.
- The Company has informed that the Company has signed its first export agreement with ZAID ELYAS ADIL LTD, Afghanistan. T
The Company has informed that the Company has signed its first export agreement with ZAID ELYAS ADIL LTD, Afghanistan. The Company will export total of 13 different medicines to Afghanistan for next 5 years commencing from August 2020. Total export value (estimated) will be 3,80,000.00 US Dollar. First export value (as per PI) will be 26,780.00 US Dollar against 13 different medicines to Afghanistan and estimated profit will be 30% against the export.
- (Q3 Un-audited): EPS was Tk. 0.25 for January-March 2020 as against Tk. 0.41 for January-March 2019; EPS was Tk. 0.76 fo
(Q3 Un-audited): EPS was Tk. 0.25 for January-March 2020 as against Tk. 0.41 for January-March 2019; EPS was Tk. 0.76 for July 2019-March 2020 as against Tk. 1.07 for July 2018-March 2019. NOCFPS was Tk. 1.22 for July 2019-March 2020 as against Tk. 0.10 for July 2018-March 2019. NAV per share was Tk. 21.60 as on March 31, 2020 and Tk. 23.12 as on June 30, 2019.
- As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on June 29, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2020.
- The Company has informed that it has credited the Bonus shares for the year ended on June 30, 2019 to the respective sha
The Company has informed that it has credited the Bonus shares for the year ended on June 30, 2019 to the respective shareholders' BO Accounts and it has also disbursed cash dividend to the respective shareholders.
- The Company will be placed in 'A' category from existing 'N' category with effect from February 03, 2020 as the Company
The Company will be placed in 'A' category from existing 'N' category with effect from February 03, 2020 as the Company has reported disbursement of 2% cash and 10% stock dividend for the year ended on June 30, 2019.
- DSE NEWS: The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase sec
DSE NEWS: The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase security of Silco Pharmaceuticals Limited in between 1st to 30th trading day after change of categorization, with effect from February 03, 2020 as per BSEC Directive No. SEC/CMRRCD/2009-193/177 and BSEC Order No. SEC/CMRRCD/2009-193/178 dated October 27, 2015.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.